PHENO LOCK
Live / Registered — Registered (as of 24 Oct 2023)
What this means for you
Registered since 24 Oct 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97626317
- Registration number
- 7201861
- Mark type
- Stylized text
- Filed
- 10 Oct 2022
- Published for opposition
- 08 Aug 2023
- Registered
- 24 Oct 2023
- Attorney of record
- Carlynn Ferguson
Goods and services
- Class 001 — Chemicals: Class 1: Chemical and biological preparations for use in science and industry; chemical and biological preparations for non-medical purposes; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations for non-medical purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely, stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; [ Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely, for medical conditions caused by the immune system; ] pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
- Class 040 — Treatment of materials: Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
Owner
- Quell Therapeutics Limited, London, GB
- Quell Therapeutics Limited, London, GB
- Quell Therapeutics Limited, London, GB
Prosecution history
- 05 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 Jun 2025 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 05 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 05 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 13 Feb 2024 — NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
- 05 Jan 2024 — AMENDMENT UNDER SECTION 7 - PROCESSED
- 04 Jan 2024 — TEAS SECTION 7 REQUEST RECEIVED
- 18 Nov 2023 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 31 Oct 2023 — TEAS SECTION 7 REQUEST RECEIVED
- 24 Oct 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Oct 2023 — REGISTERED-PRINCIPAL REGISTER
- 20 Sept 2023 — POST PUBLICATION AMENDMENT - ENTERED
- 20 Sept 2023 — ASSIGNED TO PETITION STAFF
- 29 Aug 2023 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 08 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED